Welcome to our dedicated page for Nanobiotix news (Ticker: NBTX), a resource for investors and traders seeking the latest updates and insights on Nanobiotix stock.
Nanobiotix S.A. develops nanotechnology-based therapeutic platforms for cancer and other major diseases as a late-stage clinical biotechnology company. Its news commonly centers on JNJ-1900 (NBTXR3), a hafnium oxide nanoparticle radioenhancer administered by intratumoral injection and activated by radiotherapy, including head and neck cancer and lung cancer development updates, clinical data presentations, and regulatory communications.
Company updates also cover the Nanoprimer platform for bioavailability and biodistribution, preclinical work with lipid nanoparticle-delivered therapies, collaborations with Johnson & Johnson, Janssen and MD Anderson, periodic operating and financial results, and recurring disclosures of share capital and voting rights for its Euronext Paris and Nasdaq-listed securities.
NANOBIOTIX (NASDAQ: NBTX) will report its fourth quarter and full year 2025 operational and financial results on March 31, 2026, after U.S. market close. A conference call and webcast will be held on April 1, 2026 at 8:00 AM EDT / 2:00 PM CEST.
Laurent Levy, CEO, and Bart van Rhijn, chief financial and business officer, will review year-end results and provide a business update. Webcast replay will be archived on the company website; investors may submit questions in advance via email.
NANOBIOTIX (NASDAQ: NBTX) issued a statement on March 25, 2026 addressing recent media speculation about a potential public take-over.
The company said, to its knowledge, there is no intention by any party to acquire control and no process or assessment is underway; it also identified factual inaccuracies in the report that conflict with its recent public disclosures.
Nanobiotix (Nasdaq: NBTX) disclosed its voting rights and share capital as of February 28, 2026. The company reported 48,494,528 shares outstanding, 50,197,214 theoretical voting rights, and 50,175,096 exercisable voting rights.
Listing: Euronext Paris and Nasdaq; document explains calculation of gross and net voting rights under AMF rules.
NANOBIOTIX (NASDAQ: NBTX) announced management will attend multiple investor conferences in March 2026, including TD Cowen Health Care, UBS Biotech Summit Miami, Jefferies Biotech on the Beach, and Leerink's Global Healthcare Conference.
Presenters Laurent Levy, CEO, and Bart van Rhijn, CFO & Business Officer, will host scheduled fireside chats on March 4 and March 11, 2026, with locations in Boston and Miami Beach and specific times listed for investor access.
Nanobiotix (NASDAQ: NBTX) disclosed its voting rights and share count as of January 31, 2026. The company reported 48,450,358 shares outstanding, 50,153,460 theoretical voting rights and 50,131,342 exercisable voting rights.
The release explains methodology for theoretical vs exercisable voting rights and lists contact details for investor and media relations.
Nanobiotix (Ticker: NBTX) reported its share and voting-rights counts as of December 31, 2025 in accordance with French disclosure rules.
The company shows 48,410,068 shares outstanding and a total theoretical number of voting rights of 50,109,170, with 50,087,052 exercisable voting rights.
NANOBIOTIX (NASDAQ: NBTX) disclosed its voting rights and share capital as of November 30, 2025. The company reported 48,401,118 shares outstanding, 50,101,699 theoretical (gross) voting rights and 50,079,581 exercisable (net) voting rights.
Disclosure follows French legal requirements (articles L.233-8 II and AMF Article 223-16). NANOBIOTIX is listed on Euronext Paris and Nasdaq Global Select Market and holds over 25 patent families across three nanotechnology platforms with operations in France and the United States.
NANOBIOTIX (Euronext: NANO / NASDAQ: NBTX) will be admitted to the CAC Mid 60 and SBF 120 indices on Euronext Paris, effective after market close on December 19, 2025. The company said the index inclusions follow Euronext Paris's annual review.
The announcement notes inclusion is expected to broaden visibility among institutional investors, strengthen the company’s presence in European equity markets, and increase exposure to index-linked investment strategies. Management framed the move as validation of the company’s long-term strategy as it advances late-stage clinical programs in physics-based oncology.
Nanobiotix (NASDAQ: NBTX) reported a third-quarter 2025 operational and financial update and a 2026 clinical outlook. Key items include a $50 million upfront royalty financing with HealthCare Royalty (HCRx) and an expected additional $21 million contingent payment in one year, €20.4 million cash at Sept 30, 2025, and projected cash visibility into early 2028 assuming receipt of HCRx funds. The company completed majority-region sponsorship transfer of the Phase 3 NANORAY-312 head and neck study to Johnson & Johnson, advanced the JNJ-1900 (NBTXR3) program with Phase 1 esophageal data presented, and expanded Curadigm Nanoprimer IP and preclinical work with collaborations and CMC activities.
NANOBIOTIX (Nasdaq: NBTX / Euronext: NANO) disclosed its voting rights and share capital data as of October 31, 2025. The company reports 48,237,471 shares outstanding, a theoretical total of 50,267,962 voting rights and 50,245,844 exercisable voting rights.
The notice follows French disclosure rules (AMF) and explains the difference between theoretical (gross) voting rights and exercisable (net) voting rights, excluding treasury shares. Contact details for communications and investor relations are provided.